The management of multiple sclerosis in children: a European view (Q45108726)

9 December 2017

The management of multiple sclerosis in children: a European view (English)

1 reference

9 December 2017

0 references

Sergiusz Jozwiak

9

0 references

Maria Pia Amato

Maria Pia Amato

4

0 references

Maria A Rocca

Maria A Rocca

16

0 references

Massimo Filippi

Massimo Filippi

8

0 references

Morten Blinkenberg

6

Morten Blinkenberg

1 reference

9 December 2017

1

Angelo Ghezzi

1 reference

9 December 2017

2

Brenda Banwell

1 reference

9 December 2017

Alexey Boyko

3

1 reference

9 December 2017

Banu Anlar

5

1 reference

9 December 2017

Maartje Boon

7

1 reference

9 December 2017

Immy Ketelslegers

10

1 reference

9 December 2017

Barbara Kornek

11

1 reference

9 December 2017

Ming Lim

12

1 reference

9 December 2017

Eva Lindstrom

13

1 reference

9 December 2017

Congor Nadj

14

1 reference

9 December 2017

Rinze Neuteboom

15

1 reference

9 December 2017

Kevin Rostasy

17

1 reference

9 December 2017

Marc Tardieu

18

1 reference

9 December 2017

Evangeline Wassmer

19

1 reference

9 December 2017

Coriene Catsman-Berrevoets

20

1 reference

9 December 2017

Rogier Hintzen

21

1 reference

9 December 2017

4 August 2010

1 reference

Multiple Sclerosis Journal

9 December 2017

1 reference

9 December 2017

16

1 reference

9 December 2017

10

1 reference

9 December 2017

1258-1267

1 reference

Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions

9 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Prospective study of multiple sclerosis with early onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Natural history of multiple sclerosis with childhood onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Early onset multiple sclerosis: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

The cognitive burden of multiple sclerosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Cognitive functioning in children and adolescents with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Cognitive and psychosocial features of childhood and juvenile MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Treatment of children and adolescents with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Childhood-juvenile multiple sclerosis: clinical characteristics and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Treatment of pediatric multiple sclerosis and variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Childhood multiple sclerosis treated with plasmapheresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Treatment of Early Onset Multiple Sclerosis with Suboptimal Dose of Interferon Beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Vasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Cyclophosphamide therapy in pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510375568

21 January 2018

Identifiers

DOI

10.1177/1352458510375568

1 reference

9 December 2017

1 reference